<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD v1.0 20120330//EN" "JATS-archivearticle1.dtd">
<article xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" article-type="research-article"><?properties open_access?><front><journal-meta><journal-id journal-id-type="nlm-ta">Ther Clin Risk Manag</journal-id><journal-id journal-id-type="iso-abbrev">Ther Clin Risk Manag</journal-id><journal-id journal-id-type="publisher-id">Therapeutics and Clinical Risk Management</journal-id><journal-title-group><journal-title>Therapeutics and Clinical Risk Management</journal-title></journal-title-group><issn pub-type="ppub">1176-6336</issn><issn pub-type="epub">1178-203X</issn><publisher><publisher-name>Dove Medical Press</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="pmid">29317824</article-id><article-id pub-id-type="pmc">5743125</article-id><article-id pub-id-type="doi">10.2147/TCRM.S145681</article-id><article-id pub-id-type="publisher-id">tcrm-14-031</article-id><article-categories><subj-group subj-group-type="heading"><subject>Original Research</subject></subj-group></article-categories><title-group><article-title>Selection of piperacillin/tazobactam infusion mode guided by SOFA score in cancer patients with hospital-acquired pneumonia: a randomized controlled study</article-title></title-group><contrib-group><contrib contrib-type="author" equal-contrib="yes"><name><surname>Lyu</surname><given-names>Yang</given-names></name><xref ref-type="aff" rid="af1-tcrm-14-031">1</xref><xref ref-type="author-notes" rid="fn1-tcrm-14-031">*</xref></contrib><contrib contrib-type="author" equal-contrib="yes"><name><surname>Yang</surname><given-names>Yang</given-names></name><xref ref-type="aff" rid="af2-tcrm-14-031">2</xref><xref ref-type="author-notes" rid="fn1-tcrm-14-031">*</xref></contrib><contrib contrib-type="author"><name><surname>Li</surname><given-names>Xin</given-names></name><xref ref-type="aff" rid="af3-tcrm-14-031">3</xref></contrib><contrib contrib-type="author"><name><surname>Peng</surname><given-names>Min</given-names></name><xref ref-type="aff" rid="af3-tcrm-14-031">3</xref></contrib><contrib contrib-type="author"><name><surname>He</surname><given-names>Xin</given-names></name><xref ref-type="aff" rid="af2-tcrm-14-031">2</xref></contrib><contrib contrib-type="author"><name><surname>Zhang</surname><given-names>Peng</given-names></name><xref ref-type="aff" rid="af4-tcrm-14-031">4</xref></contrib><contrib contrib-type="author"><name><surname>Dong</surname><given-names>Shangwen</given-names></name><xref ref-type="aff" rid="af4-tcrm-14-031">4</xref></contrib><contrib contrib-type="author"><name><surname>Wang</surname><given-names>Wanhua</given-names></name><xref ref-type="aff" rid="af2-tcrm-14-031">2</xref></contrib><contrib contrib-type="author"><name><surname>Wang</surname><given-names>Donghao</given-names></name><xref ref-type="aff" rid="af1-tcrm-14-031">1</xref><xref ref-type="corresp" rid="c1-tcrm-14-031"/></contrib></contrib-group><aff id="af1-tcrm-14-031">
<label>1</label>Department of Intensive Care Unit, Tianjin Medical University Cancer Institute and Hospital, National Clinical Research Center for Cancer, Key Laboratory of Cancer Prevention and Therapy, Tianjin, Tianjin&#x02019;s Clinical Research Center for Cancer</aff><aff id="af2-tcrm-14-031">
<label>2</label>Department of Anesthesia, Tianjin Medical University Cancer Institute and Hospital, National Clinical Research Center for Cancer, Key Laboratory of Cancer Prevention and Therapy, Tianjin, Tianjin&#x02019;s Clinical Research Center for Cancer</aff><aff id="af3-tcrm-14-031">
<label>3</label>Department of Intensive Care Unit, Tianjin Medical University General Hospital, Tianjin</aff><aff id="af4-tcrm-14-031">
<label>4</label>Department of Cardiothoracic Surgery, Tianjin Medical University General Hospital, Tianjin, China</aff><author-notes><corresp id="c1-tcrm-14-031">Correspondence: Donghao Wang, Department of Intensive Care Unit, Tianjin Medical University Cancer Institute and Hospital, National Clinical Research Center for Cancer, Key Laboratory of Cancer Prevention and Therapy, Tianjin, Tianjin&#x02019;s Clinical Research Center for Cancer, Huan-Hu-Xi Road, Ti-Yuan-Bei, He Xi District, Tianjin 300060, China, Tel +86 222 334 0123, Email <email>yang_lu@tmu.edu.cn</email></corresp><fn id="fn1-tcrm-14-031"><label>*</label><p>These authors contributed equally to this work</p></fn></author-notes><pub-date pub-type="collection"><year>2018</year></pub-date><pub-date pub-type="epub"><day>21</day><month>12</month><year>2017</year></pub-date><volume>14</volume><fpage>31</fpage><lpage>37</lpage><permissions><copyright-statement>&#x000a9; 2018 Lyu et al. This work is published and licensed by Dove Medical Press Limited</copyright-statement><copyright-year>2018</copyright-year><license><license-p>The full terms of this license are available at <ext-link ext-link-type="uri" xlink:href="https://www.dovepress.com/terms.php">https://www.dovepress.com/terms.php</ext-link> and incorporate the Creative Commons Attribution &#x02013; Non Commercial (unported, v3.0) License (<ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by-nc/3.0/">http://creativecommons.org/licenses/by-nc/3.0/</ext-link>). By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed.</license-p></license></permissions><abstract><sec><title>Background</title><p>This study aimed to select piperacillin/tazobactam (TZP) infusion mode guided by Sequential Organ Failure Assessment (SOFA) score in cancer patients with hospital-acquired pneumonia (HAP) postoperation.</p></sec><sec><title>Patients and methods</title><p>A total of 120 cancer patients with postoperative HAP were divided into two groups: improved administration group (L group) and conventional treatment group (Con group). The Con group received traditional infusion of TZP and the L group received it as prolonged infusion. Blood drug concentration was detected at different time points. Based on the SOFA cut-off value of 9, the patients were regrouped into M (mild) and S (severe) groups.</p></sec><sec><title>Results</title><p>Percent time that the free drug concentrations remain above the minimum inhibitory concentration (%fT&#x0003e;MIC) was longer than 5 h in L group, but &#x0003c;4 h in Con group. Administration method (<italic>p</italic>=0.033, OX value 2.796, <italic>B</italic> value 1.028, 95% CI: 0.855&#x02013;8.934) and SOFA score (<italic>p</italic>=0.038, OX value 0.080, <italic>B</italic> value &#x02212;2.522, 95% CI: 0.007&#x02013;0.874) were independent predictors of patient survival. In the S group, compared to conventional treatment, prolonged infusion mode resulted in shorter days of antibiotic use and shorter ventilator time, and achieved longer survival, better clinical efficacy, and lower 28-day mortality rate.</p></sec><sec><title>Conclusion</title><p>For cancer patients with SOFA score &#x02265;9, prolonged infusion of TZP could benefit the patients and obtain better clinical efficacy.</p></sec></abstract><kwd-group><title>Keywords</title><kwd>cancer</kwd><kwd>Sequential Organ Failure Assessment score</kwd><kwd>piperacillin</kwd><kwd>tazobactam</kwd><kwd>pneumonia</kwd><kwd>antibiotics</kwd></kwd-group></article-meta></front><body><sec sec-type="intro"><title>Introduction</title><p>With the increase in the variety of widely used antibiotics, drug-resistant strains emerge as the pathogens of hospital-acquired pneumonia (HAP), including resistant Gram-negative bacteria such as <italic>Pseudomonas aeruginosa</italic>, <italic>Acinetobacter</italic> spp., <italic>Enterobacter cloacae</italic>, <italic>Klebsiella pneumoniae</italic>, and <italic>Escherichia coli</italic> and Gram-positive methicillin-resistant <italic>Staphylococcus aureus</italic>.<xref rid="b1-tcrm-14-031" ref-type="bibr">1</xref> Maximizing the antibacterial activity of antibiotics and choosing correct, effective, safe, and economical administration of antibiotics are extremely urgent and necessary.</p><p>Percent time that the free drug concentration remains above the minimum inhibitory concentration (MIC), that is, %fT&#x0003e;MIC, is an important index of the pharmacodynamics of &#x003b2;-lactam antibiotics. Piperacillin/tazobactam (TZP) administration aims to extend %fT&#x0003e;MIC to improve clinical outcomes. In general, we can increase the dose and the frequency of administration, or extend the infusion time to increase the efficacy of the drug. However, increasing the dose and the frequency of administration would increase treatment cost and resource consumption. Therefore, we chose extending infusion time to increase the antibacterial activity of TZP and improve the clinical efficacy without increasing the dose of TZP. The severity of the patient&#x02019;s condition could determine the clinical efficacy. Therefore, we introduced the Sequential Organ Failure Assessment (SOFA) score to assess the patient&#x02019;s condition prior to administration. We hypothesized that the SOFA score could guide us in choosing the correct administration to maximize the antimicrobial activity of TZP.</p></sec><sec sec-type="methods|subjects"><title>Patients and methods</title><sec><title>Patient selection</title><p>A randomized, prospective, controlled study, approved by the Medical Ethics Committee of Tianjin Medical University Cancer Hospital with approval number E2011077A, was conducted. Written informed consent was obtained from all patients or their families. The clinical trial registration was completed and approved with registration certificate number NCT01796717 (<ext-link ext-link-type="uri" xlink:href="https://register.clini-caltrials.gov">https://register.clini-caltrials.gov</ext-link>).</p><p>The inclusion criteria were as follows: age 18&#x02013;70 years; cancer and postoperative HAP diagnosed in accordance with the Chinese Medical Association, American College of Chest Physicians, and the Society of Infectious Disease diagnostic criteria;<xref rid="b2-tcrm-14-031" ref-type="bibr">2</xref>,<xref rid="b3-tcrm-14-031" ref-type="bibr">3</xref> no cardiopulmonary disease before operations; no lung injury and respiratory dysfunction during surgery and anesthesia; no pulmonary metastasis before operations; abdominal tumor patients who had received radical resection; no bleeding, fistula, abdominal infection, and cardiac dysfunction postoperation; and the pathogens should be sensitive to TZP, with MIC of 8 or 16 mg/L.</p><p>The exclusion criteria were as follows: clinical manifestations of infection and having received systematic anti-infection treatment &#x0003e;48 h before enrolling; sepsis with hypotension and/or evidence of organ dysfunction (septic shock): systolic blood pressure &#x0003c;90 mmHg or diastolic blood pressure &#x0003c;60 mmHg, receiving vasoactive drugs &#x0003e;4 h; kidney injury: urine output &#x0003c;20 mL/h or &#x0003c;80 mL/4 h, acute renal failure, requiring blood purification treatment, creatinine clearance &#x0003c;20 mL/min; infections caused by bacteria not susceptible to TZP; recurrent lung infections caused by complicated factors such as obstructive pneumonia, lung abscess, empyema, and active tuberculosis; allergic to penicillin; pregnant or lactating women; any predictable factors which may increase the risk for patients or interfere with the results of clinical trials in patients, such as anastomotic fistula after abdominal tumor operation, acute liver failure, acute cardiac and cerebral vascular accident.</p></sec><sec><title>Treatment</title><p>Before treatment, all patients were assessed with SOFA score. In accordance with the sputum culture and susceptibility results, TZP (trade name for Tazocin) was selected for anti-infection treatment. All patients were randomly divided into the following two groups by a computer, to generate random numbers without prior restrictions or intervention or adjustment in advance or during the implementation process: improved administration group (L group, 60 cases) and conventional treatment group (Con group, 60 cases). In accordance with the &#x0201c;National Guidelines for Antimicrobial Therapy&#x0201d; issued by the Medical Administration Department of the Ministry of Health in the People&#x02019;s Republic of China, Con group received TZP at 4.5 g per 6 h and intravenous infusion was completed within 30 min; the L group received TZP at 4.5 g per 6 h with an infusion pump to extend the administration time to 3 h. The nurses in charge were blind to the grouping.</p></sec><sec><title>Determination of serum drug concentration</title><p>Two millilitres of peripheral blood was collected from all enrolled patients at 0.5, 1, 2, 3, 4, 5, and 6 h after drug administration in a heparin tube and centrifuged for 10 min, immediately. The plasma was then separated and the specimen placed at &#x02212;80&#x000b0;C.</p><p>Ultra-performance liquid chromatography tandem mass spectrometry was used to determine TZP concentration in the plasma at the Tianjin Medical University Cancer Hospital Pharmacological Laboratory.</p></sec><sec><title>Clinical therapeutic efficacy</title><p>Before and after 3 days of treatment, the two groups were compared for acute physiology and chronic health evaluation II (APACHE II) score, clinical pulmonary infection score (CPIS), and procalcitonin (PCT) level. The clinical efficacy and bacteriologic efficacy were determined in accordance with the &#x0201c;Guiding principles for clinical application of antimicrobial agents&#x0201d; issued by the General Logistics Department of the Ministry of Health in the People&#x02019;s Republic of China. The successful treatment rate of the two groups was assessed, and SOFA sensitivity and specificity were calculated for the cut-off value of SOFA score. Based on the SOFA cut-off value, patients were regrouped into mild group (M group) and severe group (S group). Based on different modes of administration of TZP, the patients in each group were divided into extending administration group (including M1 and S1 groups) and conventional treatment group (including M2 and S2 groups).</p></sec><sec sec-type="methods"><title>Statistical analysis</title><p>SPSS 19.0 statistical software was applied for data processing. Data with normal distribution were presented as mean &#x000b1; SD and compared using independent <italic>t</italic>-test. Chi-square test or Fisher&#x02019;s exact probability method was used for counting data. Cox or logistic regression was used for multivariate analysis. <italic>P</italic>&#x0003c;0.05 was considered statistically significant.</p></sec></sec><sec sec-type="results"><title>Results</title><sec sec-type="subjects"><title>Comparison of the patients in L and Con groups</title><p>In this study, we enrolled 120 patients, including 30 cases of lung cancer (25 cases of squamous cell carcinoma of the lung and five cases of lung adenocarcinoma), 56 cases of upper gastrointestinal cancer (21 cases of gastric cancer, 15 cases of hepatocellular carcinoma, six cases of cholangiocarcinoma, and 14 cases of pancreatic cancer), 30 cases of lower gastrointestinal cancer (21 cases of colon cancer and nine cases of rectal cancer), and four cases of renal carcinoma.</p><p>With regard to HAP, 29 cases had <italic>P. aeruginosa</italic>, 18 cases had <italic>Es. coli</italic>, 22 cases had <italic>K. pneumoniae</italic>, 21 cases had <italic>Acinetobacter baumannii</italic>, eight cases had <italic>Viscous serratia</italic>, and 19 cases had <italic>En. cloacae</italic> infections. Regarding incision classification, 30 cases had chest incision, 59 cases had abdominal incision, and 31 cases had thoracoabdominal incision. There were no significant differences in general data of the patients in L and Con groups before treatment (<xref ref-type="table" rid="t1-tcrm-14-031">Tables 1</xref> and <xref ref-type="table" rid="t2-tcrm-14-031">2</xref>).</p><p>However, after administration of TZP, %fT&#x0003e;MIC time was &#x0003e;5 h in L group and &#x0003c;4 h in Con group, with MIC of 8 or 16 mg/L (<xref ref-type="fig" rid="f1-tcrm-14-031">Figure 1</xref>).</p></sec><sec><title>Sensitivity and specificity of SOFA score for treatment outcome and prognosis</title><p>Cox regression analysis showed that administration method (<italic>p</italic>=0.033, OX value 2.796, <italic>B</italic> value 1.028, 95% CI: 0.855&#x02013;8.934) and SOFA score (<italic>p</italic>=0.038, OX value 0.080, <italic>B</italic> value &#x02212;2.522, 95% CI: 0.007&#x02013;0.874) were independent predictors of patient survival. APACHE II score (<italic>p</italic>=0.745, <italic>B</italic> value 0.015), CPIS score (<italic>p</italic>=0.743, <italic>B</italic> value &#x02212;0.049), oxygenation index (mmHg; <italic>p</italic>=0.212, <italic>B</italic> value 0.012), PCT (ng/mL; <italic>p</italic>=0.655, <italic>B</italic> value 0.003), albumin (g/L; <italic>p</italic>=0.127, <italic>B</italic> value &#x02212;0.118), primary disease classification (<italic>p</italic>=0.655, <italic>B</italic> value 9.066), incision classification (<italic>p</italic>=0.820, <italic>B</italic> value 0.162), and initial pathogen classification (<italic>p</italic>=0.720, <italic>B</italic> value 7.237) had no significant effect on patient survival.</p><p>Receiver operating characteristic curve analysis showed that the areas under the curve of SOFA score, APACHE II, and CPIS score were 0.726&#x000b1;0.050, 0.685&#x000b1;0.060, and 0.453&#x000b1;0.062, respectively. SOFA score had the highest area under the curve value. When the SOFA score was 9, the sensitivity was 84% and the specificity was 57%. Thus, we set the cut-off value of SOFA as 9. This value had high sensitivity and specificity to distinguish mild and severe cases and for selection of different antibiotics (<xref ref-type="fig" rid="f2-tcrm-14-031">Figure 2</xref>).</p></sec><sec sec-type="subjects"><title>Comparison of patients in M and S groups</title><p>According to the cut-off value of SOFA, the patients were divided into mild disease group (M group, SOFA &#x0003c;9) and severe group (S group, SOFA &#x02265;9). There were 53 cases in M group, including 29 cases in the prolonged administration group (M1) and 24 cases in the traditional administration group (M2). There were 67 cases in S group, including 32 cases in the prolonged administration group (S1) and 35 cases in the traditional administration group (S2). We compared the basic data of the four groups of patients before and after treatment.</p><p>First, we compared the clinical data between L and Con groups after treatment and found that prolonged infusion time of administration improved patient survival, increased clinical efficacy and bacteriologic efficacy, and reduced 28-day mortality (<italic>p</italic>&#x0003c;0.05), as shown in <xref ref-type="table" rid="t3-tcrm-14-031">Table 3</xref> and <xref ref-type="fig" rid="f3-tcrm-14-031">Figure 3</xref>.</p><p>Next, in the two mild groups M1 and M2, bacteriologic efficacy was significantly different. However, the clinical indicators of survival, days of antibiotic use, ventilator time, clinical efficacy, and 28-day mortality in the two groups showed no significant difference (<italic>p</italic>&#x0003e;0.05; <xref ref-type="table" rid="t3-tcrm-14-031">Table 3</xref>). There was no significant difference in survival between the M1 and M2 groups (<xref ref-type="fig" rid="f4-tcrm-14-031">Figure 4</xref>).</p><p>Furthermore, in the two severe groups S1 and S2, bacteriologic efficacy was significantly different. In addition, days of antibiotics use and ventilator time were shorter in S1 group than in S2 group. The patients in S1 group had longer survival, better clinical efficacy, and lower 28-day mortality rate than those in S2 group. The survival of S1 group was superior to that of S2 group (<xref ref-type="fig" rid="f5-tcrm-14-031">Figure 5</xref>).</p></sec></sec><sec sec-type="discussion"><title>Discussion</title><p>Blindly choosing the highest level of antibiotics may produce good effect in the short term, but in the long run, the consequences arising from drug resistance of bacteria may be disastrous.<xref rid="b4-tcrm-14-031" ref-type="bibr">4</xref> TZP is a mixed preparation of broad-spectrum &#x003b2;-lactam antibiotic piperacillin and &#x003b2;-lactamase inhibitor tazobactam. The %fT&#x0003e;MIC index is a measure of bactericidal effect.<xref rid="b5-tcrm-14-031" ref-type="bibr">5</xref> Increasing the dosage or the frequency of administration can show increased efficacy, but increases the medical costs and causes varying degrees of kidney damage. Prolonging the infusion time may be a desirable dosing regimen to increase drug efficacy without increasing its dosage.<xref rid="b6-tcrm-14-031" ref-type="bibr">6</xref> Our previous study showed that TZP-optimized dosing regimen of prolonging the infusion time improved clinical efficacy, shortened treatment time, and reduced medical cost.<xref rid="b7-tcrm-14-031" ref-type="bibr">7</xref> Critically ill patients are the population most likely to benefit from the optimization strategy of drug exposure.<xref rid="b8-tcrm-14-031" ref-type="bibr">8</xref>,<xref rid="b9-tcrm-14-031" ref-type="bibr">9</xref> Lodise et al found that in patients with <italic>P. aeruginosa</italic> infection and APACHE II score &#x02265;17, extending the TZP infusion time significantly reduced mortality and the number of days of hospitalization, compared to the traditional mode of administration.<xref rid="b10-tcrm-14-031" ref-type="bibr">10</xref> A recent study reported that continuous infusion of TZP achieved similar efficacy and safety to conventional intermittent infusion.<xref rid="b11-tcrm-14-031" ref-type="bibr">11</xref> However, a large multicenter study confirmed that prolonged infusion led to significantly better clinical cure and survival rates compared with intermittent infusion.<xref rid="b12-tcrm-14-031" ref-type="bibr">12</xref></p><p>In this study, we divided all patients into two groups randomly, to receive TZP in different modes of administration. We detected the plasma concentration of TZP at different time points and found that at MIC of 8 or 16 mg/L, the %fT&#x0003e;MIC was longer than 5 h in L group but &#x0003c;4 h in the control group. Statistical analysis showed that survival was better in L group than in control group, and prolonged infusion increased the clinical efficacy and bacteriologic efficacy while reducing the mortality. However, in clinical practice, we found that some patients do not need prolonged infusion of TZP, but still show good outcome. Prolonged infusion mode depends on the use of infusion pumps, which increases the cost of treatment, and it may also increase the risk of venous catheter infection.</p><p>Therefore, it is important to identify patients who need prolonged infusion mode the most. In this study, we used Cox regression analysis to compare the effects of various factors on the survival of patients and found that administration method (<italic>p</italic>=0.033, OX value 2.796, <italic>B</italic> value 1.028, 95% CI: 0.855&#x02013;8.934) and SOFA scores (<italic>p</italic>=0.038, OX value 0.080, <italic>B</italic> value &#x02212;2.522, 95% CI: 0.007&#x02013;0.874) were independent predictors of survival. SOFA score has been proposed by the European Association of Intensive Care Medicine; it is simple, objective, easily accessible, and noninvasive for the assessment of critically ill patients, and increased scores indicate more severe diseases.<xref rid="b13-tcrm-14-031" ref-type="bibr">13</xref></p><p>We recorded APACHE II score, CPIS score, PCT, treatment effect, and prognosis after the treatment. We detected the sensitivity and specificity of the SOFA score before treatment to assess the prognosis for patients and found that a SOFA cut-off value of 9 may have higher sensitivity and specificity. All patients were regrouped in accordance with this cut-off value and divided into M1, M2, S1, and S2 groups in accordance with the different modes of administration of TZP and severity of the disease.</p><p>In the mild groups M1 and M2 receiving different modes of TZP administration, the days of antibiotics use, ventilator time, clinical and bacteriologic efficacy, and even 28-day mortality and survival time had almost no significant differences between groups. However, in the severe groups S1 and S2, we found significant differences in bacteriologic efficacy, and the days of antibiotic use and the ventilator time were shorter in S1 group than in S2 group after treatment. In addition, the survival was longer, clinical efficacy was better, and 28-day mortality was lower in S1 group than in S2 group.</p><p>Therefore, for nonsevere HAP patients, we can obtain similar clinical efficacy using extended or traditional administration methods for antibiotics. However, for severe HAP patients, the selection of TZP prolonged infusion for the treatment of infection by resistant bacteria (MIC =8/16 mg/L) may highlight the advantages of %fT&#x0003e;MIC. The antibacterial activity can be maximized by choosing prolonged infusion of TZP.</p><p>Several limitations of this study should be stated. First, the sample size of this study is relatively small. Large-scale multicenter studies with more than 500 subjects are needed to confirm our conclusion. Second, we could not exclude some confounding factors that interfere with the correlation of SOFA value with different modes of administration, which may cause bias in our conclusion. Such confounding factors include organ dysfunction, especially kidney dysfunction, and circulation and respiration status. Therefore, it is important to include subjects with the same or similar status of organ function for comparison.</p><p>In conclusion, compared to the traditional infusion method of TZP, prolonged infusion exhibits better efficacy. However, not all patients can benefit from prolonged infusion. For severe patients with SOFA score &#x02265;9, prolonged infusion of TZP could show significantly better clinical efficacy.</p></sec></body><back><ack><title>Acknowledgments</title><p>The study was supported by a grant from the Science and Technology fund of Tianjin Municipal Health Bureau, China (No 2013KZ091) and the Science Foundation of Tianjin Medical University, China (No 2014KYQ10).</p></ack><fn-group><fn fn-type="COI-statement"><p><bold>Disclosure</bold></p><p>The authors report no conflicts of interest in this work.</p></fn></fn-group><ref-list><title>References</title><ref id="b1-tcrm-14-031"><label>1</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Nseir</surname><given-names>S</given-names></name><name><surname>Grailles</surname><given-names>G</given-names></name><name><surname>Soury-Lavergne</surname><given-names>A</given-names></name><name><surname>Minacori</surname><given-names>F</given-names></name><name><surname>Alves</surname><given-names>I</given-names></name><name><surname>Durocher</surname><given-names>A</given-names></name></person-group><article-title>Accuracy of American Thoracic Society/Infectious Diseases Society of America criteria in predicting infection or colonization with multidrug-resistant bacteria at intensive-care unit admission</article-title><source>Clin Microbiol Infect</source><year>2010</year><volume>16</volume><issue>7</issue><fpage>902</fpage><lpage>908</lpage><pub-id pub-id-type="pmid">19694760</pub-id></element-citation></ref><ref id="b2-tcrm-14-031"><label>2</label><element-citation publication-type="journal"><person-group person-group-type="author"><collab>Chinese Society of Respiratory Disease Association</collab></person-group><article-title>Hospital-acquired pneumonia diagnosis and treatment guidelines</article-title><source>Modern Practical Medicine</source><year>2002</year><volume>14</volume><fpage>160</fpage><lpage>161</lpage></element-citation></ref><ref id="b3-tcrm-14-031"><label>3</label><element-citation publication-type="journal"><person-group person-group-type="author"><collab>American thoracic society</collab><collab>Infectious Diseases Society of America</collab></person-group><article-title>Guidelines for the management of adults with hospital-acquired, ventilator-associated and healthcare-associated pneumonia</article-title><source>Am J Respir Crit Med</source><year>2005</year><volume>171</volume><issue>4</issue><fpage>388</fpage><lpage>416</lpage></element-citation></ref><ref id="b4-tcrm-14-031"><label>4</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Li</surname><given-names>J</given-names></name><name><surname>Song</surname><given-names>X</given-names></name><name><surname>Yang</surname><given-names>T</given-names></name><etal/></person-group><article-title>A systematic review of antibiotic prescription associated with upper respiratory tract infections in China</article-title><source>Medicine (Baltimore)</source><year>2016</year><volume>95</volume><issue>19</issue><fpage>e3587</fpage><pub-id pub-id-type="pmid">27175658</pub-id></element-citation></ref><ref id="b5-tcrm-14-031"><label>5</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zhou</surname><given-names>YF</given-names></name><name><surname>Shi</surname><given-names>W</given-names></name><etal/></person-group><article-title>Pharmacokinetic/pharmacodynamic correlation of cefquinome against experimental catheter-associated biofilm infection due to <italic>Staphylococcus aureus</italic></article-title><source>Front Microbiol</source><year>2016</year><volume>6</volume><fpage>1513</fpage><pub-id pub-id-type="pmid">26779167</pub-id></element-citation></ref><ref id="b6-tcrm-14-031"><label>6</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lee</surname><given-names>LS</given-names></name><name><surname>Kiinzig-Schippers</surname><given-names>M</given-names></name><name><surname>Nafziger</surname><given-names>AN</given-names></name><etal/></person-group><article-title>Comparison of 30 min and 3 h infusion regimens for imipenem/cilastatin and meropenem evaluated by Monte Carlo Simulation</article-title><source>Diagn Microbiol Infect Dis</source><year>2010</year><volume>68</volume><issue>3</issue><fpage>251</fpage><lpage>258</lpage><pub-id pub-id-type="pmid">20851549</pub-id></element-citation></ref><ref id="b7-tcrm-14-031"><label>7</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>L&#x000fc;</surname><given-names>Y</given-names></name><name><surname>Yan</surname><given-names>Z</given-names></name><name><surname>Wang</surname><given-names>DH</given-names></name><name><surname>Dong</surname><given-names>WL</given-names></name><name><surname>Yang</surname><given-names>Y</given-names></name><name><surname>Xia</surname><given-names>R</given-names></name></person-group><article-title>Treatment study of hospital acquired pneumonia by optimizing dosing regimen of piperacillin/tazobactam:prolonged versus. regular infusion</article-title><source>Zhonghua Wei Zhong Bing Ji Jiu Yi Xue</source><year>2013</year><volume>25</volume><issue>8</issue><fpage>479</fpage><lpage>483</lpage><comment>Chinese</comment><pub-id pub-id-type="pmid">24021044</pub-id></element-citation></ref><ref id="b8-tcrm-14-031"><label>8</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Langan</surname><given-names>KM</given-names></name><name><surname>Jacob</surname><given-names>J</given-names></name><name><surname>Li</surname><given-names>J</given-names></name><etal/></person-group><article-title>Pharmacokinetics of short versus extended infusion meropenem dosing in critically ill patients: a pilot study</article-title><source>Crit Care Resusc</source><year>2014</year><volume>16</volume><issue>3</issue><fpage>190</fpage><lpage>196</lpage><pub-id pub-id-type="pmid">25161021</pub-id></element-citation></ref><ref id="b9-tcrm-14-031"><label>9</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lee</surname><given-names>GC</given-names></name><name><surname>Liou</surname><given-names>H</given-names></name><name><surname>Yee</surname><given-names>R</given-names></name><name><surname>Quan</surname><given-names>CF</given-names></name><name><surname>Neldner</surname><given-names>K</given-names></name></person-group><article-title>Outcomes of extended-nfusion piperacillin-tazobactam: a retrospective analysis of critically ill patients</article-title><source>Clin Ther</source><year>2012</year><volume>34</volume><issue>12</issue><fpage>2297</fpage><lpage>2300</lpage><pub-id pub-id-type="pmid">23195962</pub-id></element-citation></ref><ref id="b10-tcrm-14-031"><label>10</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lodise</surname><given-names>TP</given-names><suffix>Jr</suffix></name><name><surname>Lomaestro</surname><given-names>B</given-names></name><name><surname>Drusano</surname><given-names>GL</given-names></name></person-group><article-title>Piperacillin-tazobactam for Pseudomonas aeruginosa infection: clinical implications of an extended-infusion dosing strategy</article-title><source>Clin Infect Dis</source><year>2007</year><volume>44</volume><issue>3</issue><fpage>357</fpage><lpage>363</lpage><pub-id pub-id-type="pmid">17205441</pub-id></element-citation></ref><ref id="b11-tcrm-14-031"><label>11</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Cotrina-Luque</surname><given-names>J</given-names></name><name><surname>Gil-Navarro</surname><given-names>MV</given-names></name><name><surname>Acosta-Garc&#x000ed;a</surname><given-names>H</given-names></name><etal/></person-group><article-title>Continuous versus intermittent piperacillin/tazobactam infusion in infection due to or suspected pseudomonas aeruginosa</article-title><source>Int J Clin Pharm</source><year>2016</year><volume>38</volume><issue>1</issue><fpage>70</fpage><lpage>79</lpage><pub-id pub-id-type="pmid">26474861</pub-id></element-citation></ref><ref id="b12-tcrm-14-031"><label>12</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Abdul-Aziz</surname><given-names>MH</given-names></name><name><surname>Lipman</surname><given-names>J</given-names></name><name><surname>Akova</surname><given-names>M</given-names></name><etal/><collab>DALI Study Group</collab></person-group><article-title>Is prolonged infusion of piperacillin/tazobactam and meropenem in critically ill patients associated with improved pharmacokinetic/pharmacodynamic and patient outcomes? An observation from the Defining Antibiotic Levels in Intensive care unit patients (DALI) cohort</article-title><source>J Antimicrob Chemother</source><year>2016</year><volume>71</volume><issue>1</issue><fpage>196</fpage><lpage>207</lpage><pub-id pub-id-type="pmid">26433783</pub-id></element-citation></ref><ref id="b13-tcrm-14-031"><label>13</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Peres Bota</surname><given-names>D</given-names></name><name><surname>Melot</surname><given-names>C</given-names></name><name><surname>Lopes Ferreira</surname><given-names>F</given-names></name><name><surname>Nguyen Ba</surname><given-names>V</given-names></name><name><surname>Vincent</surname><given-names>JL</given-names></name></person-group><article-title>The multiple organ dysfunction score (MODS) versus the sequential organ failure assessment (SOFA) score in outcome prediction</article-title><source>Intensive Care Med</source><year>2002</year><volume>28</volume><issue>11</issue><fpage>1619</fpage><lpage>1624</lpage><pub-id pub-id-type="pmid">12415450</pub-id></element-citation></ref></ref-list></back><floats-group><fig id="f1-tcrm-14-031" position="float"><label>Figure 1</label><caption><p>%fT&#x0003e;MIC in L group and Con group with MIC of 8 and 16 &#x000b5;g/mL.</p><p><bold>Notes:</bold> The Con group (conventional treatment group) received traditional infusion of TZP and the L group (improved administration group) received it as prolonged infusion. %fT &#x0003e;MIC represents the percent time that free drug concentrations remain above the MIC.</p><p><bold>Abbreviation:</bold> MIC, minimum inhibitory concentration.</p></caption><graphic xlink:href="tcrm-14-031Fig1"/></fig><fig id="f2-tcrm-14-031" position="float"><label>Figure 2</label><caption><p>ROC curve of SOFA score, APACHE II and CPIS score. When the SOFA score was 9, the sensitivity was 84% and the specificity was 57%.</p><p><bold>Abbreviations:</bold> APACHE II, acute physiology and chronic health evaluation II; CPIS, clinical pulmonary infection score; ROC, receiver operating characteristic; SOFA, Sequential Organ Failure Assessment.</p></caption><graphic xlink:href="tcrm-14-031Fig2"/></fig><fig id="f3-tcrm-14-031" position="float"><label>Figure 3</label><caption><p>Survival curve of L group and Con group.</p><p><bold>Note:</bold> The Con group (conventional treatment group) received traditional infusion of TZP and the L group (improved administration group) received it as prolonged infusion.</p></caption><graphic xlink:href="tcrm-14-031Fig3"/></fig><fig id="f4-tcrm-14-031" position="float"><label>Figure 4</label><caption><p>Survival curve of M1 and M2 groups.</p><p><bold>Notes:</bold> There was no significant difference in the survival time between M1 and M2 groups. The Con group (conventional treatment group) received traditional infusion of TZP and the L group (improved administration group) received it as prolonged infusion. Blood drug concentration was detected at different time points. Based on the SOFA cut-off value of 9, the patients were regrouped into M (mild) and S (severe) groups. M1: mild group with prolonged administration; M2: mild group with traditional administration.</p></caption><graphic xlink:href="tcrm-14-031Fig4"/></fig><fig id="f5-tcrm-14-031" position="float"><label>Figure 5</label><caption><p>Survival curve of S1 and S2 groups.</p><p><bold>Notes:</bold> The survival of S1 group was better than that of S2 group. The Con group (conventional treatment group) received traditional infusion of TZP and the L group (improved administration group) received it as prolonged infusion. Blood drug concentration was detected at different time points. Based on the SOFA cutoff value of 9, the patients were regrouped into M (mild) and S (severe) groups. S1: severe group with prolonged administration; S2: severe group with traditional administration.</p></caption><graphic xlink:href="tcrm-14-031Fig5"/></fig><table-wrap id="t1-tcrm-14-031" position="float"><label>Table 1</label><caption><p>The comparison of clinical data before treatment</p></caption><table frame="hsides" rules="groups"><thead><tr><th rowspan="3" valign="top" align="left" colspan="1"/><th colspan="3" valign="top" align="left" rowspan="1">L and Con groups (n =120)
<hr/></th><th colspan="3" valign="top" align="left" rowspan="1">M group (n=53)
<hr/></th><th colspan="3" valign="top" align="left" rowspan="1">S group (n=67)
<hr/></th></tr><tr><th valign="top" align="left" rowspan="1" colspan="1">L group
<hr/></th><th valign="top" align="left" rowspan="1" colspan="1">Con group
<hr/></th><th rowspan="2" valign="top" align="left" colspan="1"><italic>p</italic>-value</th><th valign="top" align="left" rowspan="1" colspan="1">M1 group
<hr/></th><th valign="top" align="left" rowspan="1" colspan="1">M2 group
<hr/></th><th rowspan="2" valign="top" align="left" colspan="1"><italic>p</italic>-value</th><th valign="top" align="left" rowspan="1" colspan="1">S1 group
<hr/></th><th valign="top" align="left" rowspan="1" colspan="1">S2 group
<hr/></th><th rowspan="2" valign="top" align="left" colspan="1"><italic>p</italic>-value</th></tr><tr><th valign="top" align="left" rowspan="1" colspan="1">(n=60)</th><th valign="top" align="left" rowspan="1" colspan="1">(n=60)</th><th valign="top" align="left" rowspan="1" colspan="1">(n=29)</th><th valign="top" align="left" rowspan="1" colspan="1">(n=24)</th><th valign="top" align="left" rowspan="1" colspan="1">(n=32)</th><th valign="top" align="left" rowspan="1" colspan="1">(n=35)</th></tr></thead><tbody><tr><td valign="top" align="left" rowspan="1" colspan="1">SOFA score</td><td valign="top" align="left" rowspan="1" colspan="1">10.77&#x000b1;5.896</td><td valign="top" align="left" rowspan="1" colspan="1">11.85&#x000b1;5.719</td><td valign="top" align="left" rowspan="1" colspan="1">0.309</td><td valign="top" align="left" rowspan="1" colspan="1">5.45&#x000b1;1.502</td><td valign="top" align="left" rowspan="1" colspan="1">5.58&#x000b1;1.442</td><td valign="top" align="left" rowspan="1" colspan="1">0.741</td><td valign="top" align="left" rowspan="1" colspan="1">15.56&#x000b1;3.732</td><td valign="top" align="left" rowspan="1" colspan="1">16.20&#x000b1;2.837</td><td valign="top" align="left" rowspan="1" colspan="1">0.432</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">APACHE II score</td><td valign="top" align="left" rowspan="1" colspan="1">20.35&#x000b1;5.272</td><td valign="top" align="left" rowspan="1" colspan="1">22.68&#x000b1;7.736</td><td valign="top" align="left" rowspan="1" colspan="1">0.056</td><td valign="top" align="left" rowspan="1" colspan="1">16.83&#x000b1;3.496</td><td valign="top" align="left" rowspan="1" colspan="1">16.04&#x000b1;3.099</td><td valign="top" align="left" rowspan="1" colspan="1">0.395</td><td valign="top" align="left" rowspan="1" colspan="1">25.25&#x000b1;4.197</td><td valign="top" align="left" rowspan="1" colspan="1">27.17&#x000b1;6.883</td><td valign="top" align="left" rowspan="1" colspan="1">0.177</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">CPIS score</td><td valign="top" align="left" rowspan="1" colspan="1">8.85&#x000b1;1.793</td><td valign="top" align="left" rowspan="1" colspan="1">8.53&#x000b1;1.546</td><td valign="top" align="left" rowspan="1" colspan="1">0.302</td><td valign="top" align="left" rowspan="1" colspan="1">8.55&#x000b1;1.429</td><td valign="top" align="left" rowspan="1" colspan="1">8.21&#x000b1;1.318</td><td valign="top" align="left" rowspan="1" colspan="1">0.368</td><td valign="top" align="left" rowspan="1" colspan="1">9.19&#x000b1;2.055</td><td valign="top" align="left" rowspan="1" colspan="1">8.69&#x000b1;1.641</td><td valign="top" align="left" rowspan="1" colspan="1">0.277</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">MIC (mg/L)</td><td valign="top" align="left" rowspan="1" colspan="1">11.07&#x000b1;3.922</td><td valign="top" align="left" rowspan="1" colspan="1">11.47&#x000b1;3.998</td><td valign="top" align="left" rowspan="1" colspan="1">0.581</td><td valign="top" align="left" rowspan="1" colspan="1">11.03&#x000b1;3.950</td><td valign="top" align="left" rowspan="1" colspan="1">11.00&#x000b1;3.956</td><td valign="top" align="left" rowspan="1" colspan="1">0.975</td><td valign="top" align="left" rowspan="1" colspan="1">11.25&#x000b1;3.992</td><td valign="top" align="left" rowspan="1" colspan="1">11.66&#x000b1;4.043</td><td valign="top" align="left" rowspan="1" colspan="1">0.680</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">OI (mmHg)</td><td valign="top" align="left" rowspan="1" colspan="1">204.42&#x000b1;34.36</td><td valign="top" align="left" rowspan="1" colspan="1">198.28&#x000b1;34.03</td><td valign="top" align="left" rowspan="1" colspan="1">0.328</td><td valign="top" align="left" rowspan="1" colspan="1">227.7&#x000b1;25.19</td><td valign="top" align="left" rowspan="1" colspan="1">225.5&#x000b1;24.15</td><td valign="top" align="left" rowspan="1" colspan="1">0.746</td><td valign="top" align="left" rowspan="1" colspan="1">182.3&#x000b1;26.31</td><td valign="top" align="left" rowspan="1" colspan="1">180.2&#x000b1;27.26</td><td valign="top" align="left" rowspan="1" colspan="1">0.751</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">PCT (ng/mL)</td><td valign="top" align="left" rowspan="1" colspan="1">6.26&#x000b1;6.950</td><td valign="top" align="left" rowspan="1" colspan="1">5.98&#x000b1;6.058</td><td valign="top" align="left" rowspan="1" colspan="1">0.815</td><td valign="top" align="left" rowspan="1" colspan="1">5.66&#x000b1;5.367</td><td valign="top" align="left" rowspan="1" colspan="1">5.56&#x000b1;7.856</td><td valign="top" align="left" rowspan="1" colspan="1">0.957</td><td valign="top" align="left" rowspan="1" colspan="1">6.21&#x000b1;5.893</td><td valign="top" align="left" rowspan="1" colspan="1">6.60&#x000b1;6.665</td><td valign="top" align="left" rowspan="1" colspan="1">0.799</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">Albumin (g/L)</td><td valign="top" align="left" rowspan="1" colspan="1">26.25&#x000b1;2.972</td><td valign="top" align="left" rowspan="1" colspan="1">26.10&#x000b1;2.874</td><td valign="top" align="left" rowspan="1" colspan="1">0.779</td><td valign="top" align="left" rowspan="1" colspan="1">26.34&#x000b1;2.349</td><td valign="top" align="left" rowspan="1" colspan="1">27.42&#x000b1;2.083</td><td valign="top" align="left" rowspan="1" colspan="1">0.088</td><td valign="top" align="left" rowspan="1" colspan="1">26.16&#x000b1;3.122</td><td valign="top" align="left" rowspan="1" colspan="1">25.54&#x000b1;3.257</td><td valign="top" align="left" rowspan="1" colspan="1">0.435</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">Ccr (mL/min)</td><td valign="top" align="left" rowspan="1" colspan="1">61.40&#x000b1;6.730</td><td valign="top" align="left" rowspan="1" colspan="1">63.43&#x000b1;7.335</td><td valign="top" align="left" rowspan="1" colspan="1">0.116</td><td valign="top" align="left" rowspan="1" colspan="1">66.38&#x000b1;6.758</td><td valign="top" align="left" rowspan="1" colspan="1">65.29&#x000b1;6.511</td><td valign="top" align="left" rowspan="1" colspan="1">0.556</td><td valign="top" align="left" rowspan="1" colspan="1">61.25&#x000b1;7.535</td><td valign="top" align="left" rowspan="1" colspan="1">60.34&#x000b1;6.183</td><td valign="top" align="left" rowspan="1" colspan="1">0.591</td></tr></tbody></table><table-wrap-foot><fn id="tfn1-tcrm-14-031"><p><bold>Notes:</bold> The Con group (conventional treatment group) received traditional infusion of TZP and the L group (improved administration group) received it as prolonged infusion. Blood drug concentration was detected at different time points. Based on the SOFA cut-off value of 9, the patients were regrouped into M (mild) and S (severe) groups. M1: mild group with prolonged administration; M2: mild group with traditional administration; S1: severe group with prolonged administration; S2: severe group with traditional administration.</p></fn><fn id="tfn2-tcrm-14-031"><p><bold>Abbreviations:</bold> APACHE II, acute physiology and chronic health evaluation II; Ccr, creatinine clearance; CPIS, clinical pulmonary infection score; MIC, minimum inhibitory concentration; OI, oxygenation index; PCT, procalcitonin; SOFA, Sequential Organ Failure Assessment.</p></fn></table-wrap-foot></table-wrap><table-wrap id="t2-tcrm-14-031" position="float"><label>Table 2</label><caption><p>The comparison of general data before treatment</p></caption><table frame="hsides" rules="groups"><thead><tr><th rowspan="3" valign="top" align="left" colspan="1"/><th colspan="3" valign="top" align="left" rowspan="1">L and Con groups (n=120)
<hr/></th><th colspan="3" valign="top" align="left" rowspan="1">M group (n=53)
<hr/></th><th colspan="3" valign="top" align="left" rowspan="1">S group (n=67)
<hr/></th></tr><tr><th valign="top" align="left" rowspan="1" colspan="1">L group
<hr/></th><th valign="top" align="left" rowspan="1" colspan="1">Con group
<hr/></th><th rowspan="2" valign="top" align="left" colspan="1"><italic>p</italic>-value</th><th valign="top" align="left" rowspan="1" colspan="1">M1 group
<hr/></th><th valign="top" align="left" rowspan="1" colspan="1">M2 group
<hr/></th><th rowspan="2" valign="top" align="left" colspan="1"><italic>p</italic>-value</th><th valign="top" align="left" rowspan="1" colspan="1">S1 group
<hr/></th><th valign="top" align="left" rowspan="1" colspan="1">S2 group
<hr/></th><th rowspan="2" valign="top" align="left" colspan="1"><italic>p</italic>-value</th></tr><tr><th valign="top" align="left" rowspan="1" colspan="1">(n=60)</th><th valign="top" align="left" rowspan="1" colspan="1">(n=60)</th><th valign="top" align="left" rowspan="1" colspan="1">(n=29)</th><th valign="top" align="left" rowspan="1" colspan="1">(n=24)</th><th valign="top" align="left" rowspan="1" colspan="1">(n=32)</th><th valign="top" align="left" rowspan="1" colspan="1">(n=35)</th></tr></thead><tbody><tr><td valign="top" align="left" rowspan="1" colspan="1">Age (years)</td><td valign="top" align="left" rowspan="1" colspan="1">67.40&#x000b1;7.727</td><td valign="top" align="left" rowspan="1" colspan="1">69.50&#x000b1;6.604</td><td valign="top" align="left" rowspan="1" colspan="1">0.112</td><td valign="top" align="left" rowspan="1" colspan="1">67.34&#x000b1;7.898</td><td valign="top" align="left" rowspan="1" colspan="1">69.9&#x000b1;6.171</td><td valign="top" align="left" rowspan="1" colspan="1">0.200</td><td valign="top" align="left" rowspan="1" colspan="1">67.5&#x000b1;7.573</td><td valign="top" align="left" rowspan="1" colspan="1">69.2&#x000b1;7.051</td><td valign="top" align="left" rowspan="1" colspan="1">0.337</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">Gender (male/female)</td><td valign="top" align="left" rowspan="1" colspan="1">37/23</td><td valign="top" align="left" rowspan="1" colspan="1">29/31</td><td valign="top" align="left" rowspan="1" colspan="1">0.144</td><td valign="top" align="left" rowspan="1" colspan="1">17/12</td><td valign="top" align="left" rowspan="1" colspan="1">11/13</td><td valign="top" align="left" rowspan="1" colspan="1">0.358</td><td valign="top" align="left" rowspan="1" colspan="1">20/12</td><td valign="top" align="left" rowspan="1" colspan="1">18/17</td><td valign="top" align="left" rowspan="1" colspan="1">0.365</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">BMI (kg/m<sup>2</sup>)</td><td valign="top" align="left" rowspan="1" colspan="1">22.37&#x000b1;1.946</td><td valign="top" align="left" rowspan="1" colspan="1">23.29&#x000b1;4.033</td><td valign="top" align="left" rowspan="1" colspan="1">0.109</td><td valign="top" align="left" rowspan="1" colspan="1">22.23&#x000b1;1.868</td><td valign="top" align="left" rowspan="1" colspan="1">23.25&#x000b1;3.802</td><td valign="top" align="left" rowspan="1" colspan="1">0.210</td><td valign="top" align="left" rowspan="1" colspan="1">22.45&#x000b1;2.012</td><td valign="top" align="left" rowspan="1" colspan="1">23.36&#x000b1;4.285</td><td valign="top" align="left" rowspan="1" colspan="1">0.273</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">Primary disease (cases)</td><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1">0.332</td><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1">0.710</td><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1">0.877</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">&#x02003;Lung cancer</td><td valign="top" align="left" rowspan="1" colspan="1">14</td><td valign="top" align="left" rowspan="1" colspan="1">16</td><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1">9</td><td valign="top" align="left" rowspan="1" colspan="1">4</td><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1">8</td><td valign="top" align="left" rowspan="1" colspan="1">8</td><td valign="top" align="left" rowspan="1" colspan="1"/></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">&#x02003;UGC</td><td valign="top" align="left" rowspan="1" colspan="1">26</td><td valign="top" align="left" rowspan="1" colspan="1">30</td><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1">11</td><td valign="top" align="left" rowspan="1" colspan="1">13</td><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1">15</td><td valign="top" align="left" rowspan="1" colspan="1">16</td><td valign="top" align="left" rowspan="1" colspan="1"/></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">&#x02003;LGC</td><td valign="top" align="left" rowspan="1" colspan="1">18</td><td valign="top" align="left" rowspan="1" colspan="1">12</td><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1">6</td><td valign="top" align="left" rowspan="1" colspan="1">7</td><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1">7</td><td valign="top" align="left" rowspan="1" colspan="1">11</td><td valign="top" align="left" rowspan="1" colspan="1"/></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">&#x02003;Other cancers</td><td valign="top" align="left" rowspan="1" colspan="1">2</td><td valign="top" align="left" rowspan="1" colspan="1">2</td><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1">3</td><td valign="top" align="left" rowspan="1" colspan="1">0</td><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1">2</td><td valign="top" align="left" rowspan="1" colspan="1">0</td><td valign="top" align="left" rowspan="1" colspan="1"/></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">Incision site (cases)</td><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1">0.698</td><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1">0.175</td><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1">0.869</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">&#x02003;Chest incision</td><td valign="top" align="left" rowspan="1" colspan="1">14</td><td valign="top" align="left" rowspan="1" colspan="1">16</td><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1">9</td><td valign="top" align="left" rowspan="1" colspan="1">4</td><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1">8</td><td valign="top" align="left" rowspan="1" colspan="1">8</td><td valign="top" align="left" rowspan="1" colspan="1"/></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">&#x02003;Abdominal incision</td><td valign="top" align="left" rowspan="1" colspan="1">33</td><td valign="top" align="left" rowspan="1" colspan="1">26</td><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1">14</td><td valign="top" align="left" rowspan="1" colspan="1">12</td><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1">16</td><td valign="top" align="left" rowspan="1" colspan="1">18</td><td valign="top" align="left" rowspan="1" colspan="1"/></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">&#x02003;TI</td><td valign="top" align="left" rowspan="1" colspan="1">13</td><td valign="top" align="left" rowspan="1" colspan="1">18</td><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1">6</td><td valign="top" align="left" rowspan="1" colspan="1">8</td><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1">8</td><td valign="top" align="left" rowspan="1" colspan="1">9</td><td valign="top" align="left" rowspan="1" colspan="1"/></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">Initial pathogen (cases)</td><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1">0.860</td><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1">0.407</td><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1">0.833</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">&#x02003;PA</td><td valign="top" align="left" rowspan="1" colspan="1">14</td><td valign="top" align="left" rowspan="1" colspan="1">15</td><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1">10</td><td valign="top" align="left" rowspan="1" colspan="1">9</td><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1">6</td><td valign="top" align="left" rowspan="1" colspan="1">6</td><td valign="top" align="left" rowspan="1" colspan="1"/></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">&#x02003;EC</td><td valign="top" align="left" rowspan="1" colspan="1">7</td><td valign="top" align="left" rowspan="1" colspan="1">11</td><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1">4</td><td valign="top" align="left" rowspan="1" colspan="1">4</td><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1">3</td><td valign="top" align="left" rowspan="1" colspan="1">8</td><td valign="top" align="left" rowspan="1" colspan="1"/></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">&#x02003;KP</td><td valign="top" align="left" rowspan="1" colspan="1">15</td><td valign="top" align="left" rowspan="1" colspan="1">7</td><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1">4</td><td valign="top" align="left" rowspan="1" colspan="1">4</td><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1">8</td><td valign="top" align="left" rowspan="1" colspan="1">6</td><td valign="top" align="left" rowspan="1" colspan="1"/></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">&#x02003;AB</td><td valign="top" align="left" rowspan="1" colspan="1">12</td><td valign="top" align="left" rowspan="1" colspan="1">9</td><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1">1</td><td valign="top" align="left" rowspan="1" colspan="1">4</td><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1">9</td><td valign="top" align="left" rowspan="1" colspan="1">5</td><td valign="top" align="left" rowspan="1" colspan="1"/></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">&#x02003;SM</td><td valign="top" align="left" rowspan="1" colspan="1">2</td><td valign="top" align="left" rowspan="1" colspan="1">6</td><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1">2</td><td valign="top" align="left" rowspan="1" colspan="1">3</td><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1">1</td><td valign="top" align="left" rowspan="1" colspan="1">4</td><td valign="top" align="left" rowspan="1" colspan="1"/></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">&#x02003;EC</td><td valign="top" align="left" rowspan="1" colspan="1">9</td><td valign="top" align="left" rowspan="1" colspan="1">10</td><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1">6</td><td valign="top" align="left" rowspan="1" colspan="1">0</td><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1">4</td><td valign="top" align="left" rowspan="1" colspan="1">6</td><td valign="top" align="left" rowspan="1" colspan="1"/></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">&#x02003;Other</td><td valign="top" align="left" rowspan="1" colspan="1">1<xref ref-type="table-fn" rid="tfn3-tcrm-14-031">a</xref></td><td valign="top" align="left" rowspan="1" colspan="1">2<xref ref-type="table-fn" rid="tfn4-tcrm-14-031">b</xref></td><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1">2</td><td valign="top" align="left" rowspan="1" colspan="1">0</td><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1">1</td><td valign="top" align="left" rowspan="1" colspan="1">0</td><td valign="top" align="left" rowspan="1" colspan="1"/></tr></tbody></table><table-wrap-foot><fn><p><bold>Notes:</bold></p></fn><fn id="tfn3-tcrm-14-031"><label>a</label><p><italic>Proteus mirabilis</italic>;</p></fn><fn id="tfn4-tcrm-14-031"><label>b</label><p><italic>Acinetobacter junii</italic>. The Con group (conventional treatment group) received traditional infusion of TZP and the L group (improved administration group) received it as prolonged infusion. Blood drug concentration was detected at different time points. Based on the SOFA cut-off value of 9, the patients were regrouped into M (mild) and S (severe) groups. M1: mild group with prolonged administration; M2: mild group with traditional administration; S1: severe group with prolonged administration; S2: severe group with traditional administration.</p></fn><fn id="tfn5-tcrm-14-031"><p><bold>Abbreviations:</bold> AB, <italic>Acinetobacter baumannii</italic>; BMI, body mass index; EC, <italic>Enterobacter cloacae</italic>; EC, <italic>Escherichia coli</italic>; KP, <italic>Klebsiella pneumonia</italic>e; LGC, lower gastrointestinal cancer; PA, <italic>Pseudomonas aeruginosa</italic>; SM, <italic>Serratia marcescens</italic>; TI, thoracoabdominal incision; UGC, upper gastrointestinal cancer.</p></fn></table-wrap-foot></table-wrap><table-wrap id="t3-tcrm-14-031" position="float"><label>Table 3</label><caption><p>The comparison of clinical data in each group after treatment</p></caption><table frame="hsides" rules="groups"><thead><tr><th rowspan="3" valign="top" align="left" colspan="1"/><th colspan="3" valign="top" align="left" rowspan="1">L and Con groups (n =120)
<hr/></th><th colspan="3" valign="top" align="left" rowspan="1">M group (n=53)
<hr/></th><th colspan="3" valign="top" align="left" rowspan="1">S group (n=67)
<hr/></th></tr><tr><th valign="top" align="left" rowspan="1" colspan="1">L group
<hr/></th><th valign="top" align="left" rowspan="1" colspan="1">Con group
<hr/></th><th rowspan="2" valign="top" align="left" colspan="1"><italic>p</italic>-value</th><th valign="top" align="left" rowspan="1" colspan="1">M1 group
<hr/></th><th valign="top" align="left" rowspan="1" colspan="1">M2 group
<hr/></th><th rowspan="2" valign="top" align="left" colspan="1"><italic>p</italic>-value</th><th valign="top" align="left" rowspan="1" colspan="1">S1 group
<hr/></th><th valign="top" align="left" rowspan="1" colspan="1">S2 group
<hr/></th><th rowspan="2" valign="top" align="left" colspan="1"><italic>p</italic>-value</th></tr><tr><th valign="top" align="left" rowspan="1" colspan="1">(n=60)</th><th valign="top" align="left" rowspan="1" colspan="1">(n=60)</th><th valign="top" align="left" rowspan="1" colspan="1">(n=29)</th><th valign="top" align="left" rowspan="1" colspan="1">(n=24)</th><th valign="top" align="left" rowspan="1" colspan="1">(n=32)</th><th valign="top" align="left" rowspan="1" colspan="1">(n=35)</th></tr></thead><tbody><tr><td valign="top" align="left" rowspan="1" colspan="1">Antibiotic usage (days)</td><td valign="top" align="left" rowspan="1" colspan="1">11.121&#x000b1;0.772</td><td valign="top" align="left" rowspan="1" colspan="1">13.227&#x000b1;0.605</td><td valign="top" align="left" rowspan="1" colspan="1">0.124</td><td valign="top" align="left" rowspan="1" colspan="1">11.48&#x000b1;3.55</td><td valign="top" align="left" rowspan="1" colspan="1">10.42&#x000b1;2.569</td><td valign="top" align="left" rowspan="1" colspan="1">0.225</td><td valign="top" align="left" rowspan="1" colspan="1">12.94&#x000b1;3.340</td><td valign="top" align="left" rowspan="1" colspan="1">14.66&#x000b1;3.386</td><td valign="top" align="left" rowspan="1" colspan="1">0.041</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">Ventilator time (h)</td><td valign="top" align="left" rowspan="1" colspan="1">145.95&#x000b1;21.46</td><td valign="top" align="left" rowspan="1" colspan="1">152.01&#x000b1;35.78</td><td valign="top" align="left" rowspan="1" colspan="1">0.515</td><td valign="top" align="left" rowspan="1" colspan="1">5.79&#x000b1;4.15</td><td valign="top" align="left" rowspan="1" colspan="1">6.13&#x000b1;4.28</td><td valign="top" align="left" rowspan="1" colspan="1">0.956</td><td valign="top" align="left" rowspan="1" colspan="1">126.09&#x000b1;12.91</td><td valign="top" align="left" rowspan="1" colspan="1">169.36&#x000b1;16.45</td><td valign="top" align="left" rowspan="1" colspan="1">0.043</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">Survival time (days)</td><td valign="top" align="left" rowspan="1" colspan="1">27.77&#x000b1;0.127</td><td valign="top" align="left" rowspan="1" colspan="1">24.15&#x000b1;1.029</td><td valign="top" align="left" rowspan="1" colspan="1">0.027</td><td valign="top" align="left" rowspan="1" colspan="1">28.00&#x000b1;0.00</td><td valign="top" align="left" rowspan="1" colspan="1">27.17&#x000b1;4.082</td><td valign="top" align="left" rowspan="1" colspan="1">0.276</td><td valign="top" align="left" rowspan="1" colspan="1">27.56&#x000b1;1.243</td><td valign="top" align="left" rowspan="1" colspan="1">21.69&#x000b1;9.048</td><td valign="top" align="left" rowspan="1" colspan="1">0.001</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">Clinical efficacy (%)</td><td valign="top" align="left" rowspan="1" colspan="1">88.33</td><td valign="top" align="left" rowspan="1" colspan="1">86.67</td><td valign="top" align="left" rowspan="1" colspan="1">0.044</td><td valign="top" align="left" rowspan="1" colspan="1">96.55</td><td valign="top" align="left" rowspan="1" colspan="1">96.55</td><td valign="top" align="left" rowspan="1" colspan="1">0.448</td><td valign="top" align="left" rowspan="1" colspan="1">78.13</td><td valign="top" align="left" rowspan="1" colspan="1">57.14</td><td valign="top" align="left" rowspan="1" colspan="1">0.007</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">BE (%)</td><td valign="top" align="left" rowspan="1" colspan="1">98.33</td><td valign="top" align="left" rowspan="1" colspan="1">75.00</td><td valign="top" align="left" rowspan="1" colspan="1">0.000</td><td valign="top" align="left" rowspan="1" colspan="1">100.00</td><td valign="top" align="left" rowspan="1" colspan="1">83.33</td><td valign="top" align="left" rowspan="1" colspan="1">0.011</td><td valign="top" align="left" rowspan="1" colspan="1">96.88</td><td valign="top" align="left" rowspan="1" colspan="1">71.43</td><td valign="top" align="left" rowspan="1" colspan="1">0.005</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">28-day mortality (%)</td><td valign="top" align="left" rowspan="1" colspan="1">1.67</td><td valign="top" align="left" rowspan="1" colspan="1">8.33</td><td valign="top" align="left" rowspan="1" colspan="1">0.023</td><td valign="top" align="left" rowspan="1" colspan="1">0.00</td><td valign="top" align="left" rowspan="1" colspan="1">0.00</td><td valign="top" align="left" rowspan="1" colspan="1">1.000</td><td valign="top" align="left" rowspan="1" colspan="1">3.12</td><td valign="top" align="left" rowspan="1" colspan="1">14.29</td><td valign="top" align="left" rowspan="1" colspan="1">0.027</td></tr></tbody></table><table-wrap-foot><fn id="tfn6-tcrm-14-031"><p><bold>Notes:</bold> The Con group (conventional treatment group) received traditional infusion of TZP and the L group (improved administration group) received it as prolonged infusion. Blood drug concentration was detected at different time points. Based on the SOFA cut-off value of 9, the patients were regrouped into M (mild) and S (severe) groups. M1: mild group with prolonged administration; M2: mild group with traditional administration; S1: severe group with prolonged administration; S2: severe group with traditional administration.</p></fn><fn id="tfn7-tcrm-14-031"><p><bold>Abbreviation:</bold> BE, bacteriologic efficacy.</p></fn></table-wrap-foot></table-wrap></floats-group></article>